Amryt Pharma plc

Climate Impact & Sustainability Data (2018, 2020, 2020-07-31)

Total Carbon Emissions:441.38 tCO2e/year

Total Energy Consumption:1,639,966 KWh/year

Augmented senior management team to ensure adequate resources for growth and Oleogel-S10 launch.

Established a Compliance Committee in 2019 to oversee compliance with laws, regulations, internal procedures, and industry standards.

Long-term Goals:

Medium-term Goals:

Complete regulatory filings and commercialize Oleogel-S10 for the treatment of severe EB.
Leverage global infrastructure to commercialize development-stage pipeline assets.

Short-term Goals:

Expand market opportunity for lomitapide and metreleptin by seeking approval for new indications.

Challenges presented by COVID-19 pandemic.
Dependence on two products, lomitapide and metreleptin, for revenue generation.
Competition from other biotechnology and pharmaceutical companies.
Difficulty in obtaining and maintaining adequate coverage and reimbursement for products.
Extensive governmental price controls and market regulations outside the US.
Lengthy and time-consuming regulatory approval processes.
Extensive legal and compliance obligations.
Challenges in obtaining, maintaining, enforcing, and defending intellectual property rights.
Potential infringement of intellectual property rights of others.
Legal, political, and economic uncertainty surrounding Brexit.

Team and business model proved resilient to COVID-19 challenges.
Focus on continuous product development, revenue expansion, and cash generation.
Strengthening inventory levels of metreleptin and lomitapide.
Robust supply chain.
Leveraging global commercial and medical infrastructure for efficient commercialization.
Strong patent protection and regulatory exclusivity.
Implementing and complying with settlement agreements with government agencies.
Protecting and enforcing intellectual property rights.
Monitoring and managing risks related to Brexit.

COVID-19 disruptions affecting business, preclinical studies, and clinical trials.
High incidence of delay or failure in biopharmaceutical product development.
Uncertainty and potential negative impacts from Brexit.

Closed executive offices, limited staff in manufacturing facilities, and monitored COVID-19 situation closely.
Continued efforts to develop new products and recruit qualified research partners.
Monitored Brexit developments and potential impacts on operations.